Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children

Sodiomon B Sirima, Alfred B Tiono, Alphonse Ouédraogo, Amidou Diarra, André Lin Ouédraogo, Jean Baptiste Yaro, Espérance Ouédraogo, Adama Gansané, Edith C Bougouma, Amadou T Konaté, Youssouf Kaboré, Abdoulaye Traoré, Roma Chilengi, Issiaka Soulama, Adrian J F Luty, Pierre Druilhe, Simon Cousens, Issa Nébié, Sodiomon B Sirima, Alfred B Tiono, Alphonse Ouédraogo, Amidou Diarra, André Lin Ouédraogo, Jean Baptiste Yaro, Espérance Ouédraogo, Adama Gansané, Edith C Bougouma, Amadou T Konaté, Youssouf Kaboré, Abdoulaye Traoré, Roma Chilengi, Issiaka Soulama, Adrian J F Luty, Pierre Druilhe, Simon Cousens, Issa Nébié

Abstract

Background: A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve parasite killing in vitro, while a phase Ib trial in semi-immune adult volunteers in Burkina Faso confirmed that the vaccine was safe. The aim of this study was to assess the safety and immunogenicity of this vaccine candidate in children aged 12-24 months living in malaria endemic area of Burkina Faso.

Methods: The study was a double-blind, randomized, controlled, dose escalation phase Ib trial, designed to assess the safety, reactogenicity and immunogenicity of three doses of either 15 or 30 microg of MSP3-LSP adsorbed on aluminum hydroxide in 45 children 12 to 24 months of age randomized into three equal groups. Each group received 3 vaccine doses (on days 0, 28 and 56) of either 15 microg of MSP3-LSP, 30 microg of MSP3-LSP or of the Engerix B hepatitis B vaccine. Children were visited at home daily for the 6 days following each vaccination to solicit symptoms which might be related to vaccination. Serious adverse events occurring during the study period (1 year) were recorded. Antibody responses to MSP3-LSP were measured on days 0, 28, 56 and 84.

Results: All 45 enrolled children received three MSP3 vaccine doses. No serious adverse events were reported. Most of the adverse events reported were mild to moderate in severity. The only reported local symptoms with grade 3 severity were swelling and induration, with an apparently dose related response. All grade 3 adverse events resolved without any sequelae. Both MSP3 doses regimens were able to elicit high levels of anti-MSP3 specific IgG1 and IgG3 antibodies in the volunteers with very little or no increase in IgG2, IgG4 and IgM classes: i.e. vaccination induced predominantly the isotypes involved in the monocyte-dependent mechanism of P. falciparum parasite-killing.

Conclusion: Our results support the promise of MSP3-LSP as a malaria vaccine candidate, both in terms of tolerability and of immunogenicity. Further assessment of the efficacy of this vaccine is recommended.

Trial registration: ClinicalTrials.gov NCT00452088.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.
Figure 2. Total IgG and IgM antibody…
Figure 2. Total IgG and IgM antibody responses to MSP3-LSP by vaccine group.
Symbols represent individual value of antibody measured by ELISA in a vaccine group and continuous line connects median values of arbitrary units of antibody responses to MSP3-LSP at different time points by vaccine groups: ▴ Full triangles and line in blue for MSP3-LSP (15 µg) group. • Full circles and line in red for MSP3-LSP (30 µg) group. x Cross symbols and line in black for Engerix group.
Figure 3. Antibody responses of IgG subclasses…
Figure 3. Antibody responses of IgG subclasses to MSP3-LSP by vaccine group.
Symbols represent individual value of antibody measured by ELISA in a vaccine group and continuous line connects median values of arbitrary units of antibody responses to MSP3-LSP at different time points by vaccine groups: ▴ Full triangles and line in blue for MSP3-LSP (15 µg) group. • Full circles and line in red for MSP3-LSP (30 µg) group. x Cross symbols and line in black for Engerix group.

References

    1. Guerin PJ, Olliaro P, Nosten F, Druilhe P, Laxminarayan R, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis. 2002;2(9):564–573.
    1. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun. 2004;72(1):247–252.
    1. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, et al. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun. 2000;68(5):2617–2620.
    1. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood. 1994;84(5):1594–1602.
    1. Tebo AE, Kremsner PG, Luty AJ. Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp Parasitol. 2001;98(1):20–28.
    1. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis. 2000;181(3):1202–1205.
    1. Druilhe P, Bouharoun-Tayoun H. Antibody-dependent cellular inhibition assay. Methods Mol Med. 2002;72:529–534.
    1. Ndungu FM, Bull PC, Ross A, Lowe BS, Kabiru E, et al. Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol. 2002;24(2):77–82.
    1. Jordan SJ, Branch OH, Castro JC, Oster RA, Rayner JC. Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hypoendemic transmission environment. Am J Trop Med Hyg. 2009;80(3):479–486.
    1. Audran R, Cachat M, Lurati F, Soe S, Leroy O, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun. 2005;73(12):8017–8026.
    1. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2005;2(11):e344.
    1. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine. 2007;25(14):2723–2732.
    1. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun. 2008;76(2):759–766.
    1. McColl DJ, Anders RF. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol. 1997;90(1):21–31.
    1. Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun. 1992;60(4):1473–1481.
    1. Bouharoun-Tayoun H, Druilhe P. Antibodies in falciparum malaria: what matters most, quantity or quality? Mem Inst Oswaldo Cruz. 1992;87(Suppl 3):229–234.
    1. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. 1991;45(3):297–308.
    1. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, et al. A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol. 2007;178(5):3099–3106.
    1. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990;172(6):1633–1641.
    1. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med. 1995;182(2):409–418.
    1. Druilhe P, Perignon JL. Mechanisms of defense against P. falciparum asexual blood stages in humans. Immunol Lett. 1994;41(2–3):115–120.
    1. Oeuvray C, Bouharoun-Tayoun H, Grass-Masse H, Lepers JP, Ralamboranto L, et al. A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem Inst Oswaldo Cruz. 1994;89(Suppl 2):77–80.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅